Search
REIN-2 clinical trial
Design:
- multicentre, randomised controlled trial
- 338 patients with non-diabetic proteinuric nephropathies treated with ACE inhibitor ramipril (2.5-5 mg/day) median follow-up of 19 months
Experimental groups:
- conventional (diastolic <90 mm Hg; n=169) vs intensified (systolic/diastolic <130/80 mm Hg; n=169) blood-pressure control
- dihydropyridine calcium-channel blocker felodipine (5-10 mg/day) used for intensified blood pressure control
Primary outcome:
- time to end-stage renal disease
Analysis by intention to treat
Results:
1) 38/167 (23%) intensified group & 34/168 (20%) of conventional control progressed to end-stage renal disease (hazard ratio 1.00
2) no added benefit of further blood-pressure reduction by felodipine
Related
chronic renal failure (CRF)
felodipine (Plendil)
ramipril (Altace)
General
nephrology
clinical trial
References
- Journal Watch 25(9):72, 2005
Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B,
Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D,
Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G,
Zoccali C, Remuzzi G; REIN-2 Study Group.
Blood-pressure control for renoprotection in patients with
non-diabetic chronic renal disease (REIN-2): multicentre,
randomised controlled trial.
Lancet. 2005 Mar 12;365(9463):939-46.
PMID: 15766995
- De Jong PE, de Zeeuw D.
Renoprotective therapy: is it blood pressure or albuminuria that matters?
Lancet. 2005 Mar 12;365(9463):913-4. No abstract available.
PMID: 15766975